cantly reduces postprandial and fasting plasma glucose in subjects with type 2 di-abetes. J Clin Endocrinol Metab 88:3082– 3089, 2003 12. Fineman MS, Bicsak TA, Shen LZ, Taylor K, Gaines E, Varns A, Kim D, Baron AD:Effect on glycemic control of exenatide(synthetic exendin-4) additive to existingmetformin and/or sulfonylurea treatmentin patients with type 2 diabetes. Diabetes Care 26:2370–2377, 2003 13. Nielsen LL, Baron AD: Pharmacology of exenatide (synthetic exendin-4) for thetreatment of type 2 diabetes. Curr Opinion Investig Drugs 4:401–405, 2003 14. Young AA, Gedulin BR, Bhavsar S, Bodkin N, Jodka C, Hansen B, Denaro M: Glu-cose-lowering and insulin-sensitizing ac-tions of exendin-4: studies in obesediabetic ( ob/ob, db/db ) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys(Macaca mulatta ).Diabetes 48:1026– 1034, 1999 15. Parkes DG, Pittner R, Jodka C, Smith P,